Androgen synthesis inhibitors in the treatment of castration-resistant prostate cancer
Suppression of gonadal testosterone synthesis represents the standard first line therapy for treatment of metastatic prostate cancer. However, in the majority of patients who develop castration-resistant prostate cancer (CRPC), it is possible to detect persistent activation of the androgen receptor...
| Main Authors: | , , , , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Medknow Publications & Media Pvt Ltd
2014
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4023364/ |